microdosing glp 1 agonists GLP‑1 Houston Let’s talk GLP-1s & microdosing

Older adults, vegans and vegetarians, and people on long-term acid-reducing medication often run on the lower end of optimal range without obvious symptoms

Precautions: If abnormal symptoms or side effects such as red blotches, swelling or itching occur while using the product and/or when the skin is exposed to direct sunlight after using it, consult a dermatologist

Maintain adequate nutrition: Ensure sufficient carbohydrate, protein, and overall caloric intake to support research protocol Assess joint and neurological symptoms: Monitor for swelling, carpal tunnel symptoms, or other adverse effects regularly Periodic biomarker assessment: Re-check glucose, lipids, and metabolic markers at mid-point and end of protocol Plan discontinuation protocol: Gradually reduce dosing over 1-2 weeks at research conclusion rather than abrupt cessation Post-research assessment: Verify that all parameters (glucose, lipids, metrics, symptoms) return to baseline after discontinuation Conclusion IGF-1 LR3 has a generally favourable safety profile when used in research with appropriate doses, duration, and monitoring protocols

It is divided into the sympathetic ("fight or flight") and parasympathetic ("rest and digest") branches

Verloop H, Smit JW, Dekkers OM